Acorda Therapeutics to Present Update on Phase 3 Study of CVT-301 in Parkinsonís Patients

(May 22, 2017) – Acorda Therapeutics will soon release data on its Phase 3 trial investigating the experimental drug CVT-301 as a potential therapy for patients with Parkinson’s disease. Acorda will present its poster at the International Congress of Parkinson’s Disease and Movement Disorders in Vancouver on June 5th. Read more